Human B1 cells and uses thereof
View Patent ↗The present invention is directed to isolated populations of human natural immunoglobulin-producing B1 lymphocytes, wherein the B1 lymphocytes display surface biomarkers CD20, CD43 and CD27 and are either CD11b+ or GD11b−. The present invention is also directed to a method of isolating human natural immunoglobulin-producing B1 lymphocytes from a blood sample comprising isolating B lymphocytes from the sample that express surface biomarkers CD20, CD43 and CD27, and, optionally, CD11b. In addition, the present invention is directed to a methods for diagnosing a B1 cell disorder in a patient, determining the prognosis of a patient having a B1 cell disorder, and treating a patient having a B1 cell disorder.
1. A method of isolating a population of human natural immunoglobulin-producing B1 lymphocytes from a human blood sample, wherein the B1 lymphocytes co-express surface biomarkers CD20 and CD43 and CD27, comprising isolating B lymphocytes from the sample that co-express surface biomarkers CD20 and CD43 and CD27 by contacting the sample with fluorescently labelled antibodies directed to CD20 and CD43 and CD27 and obtaining the fluorescently labelled B1 lymphocytes by fluorescence-activated cell sorting (FACS).
2. The method of claim 1 , wherein the sample is umbilical cord blood or peripheral blood.
3. The method of claim 1 , wherein the B1 lymphocytes co-express surface biomarker CD11b.
4. The method of claim 1 , wherein the B1 lymphocytes do not co-express surface biomarker CD11b.
5. The method of claim 1 , further comprising obtaining mononuclear cells in the sample via density gradient separation prior to contacting with labelled antibodies.
6. The method of claim 1 , further comprising culturing isolated B1 lymphocytes co-expressing surface biomarkers CD20 and CD43 and CD27 obtained by the method.